NASDAQ: ROIV
Roivant Sciences Ltd Stock

$10.99+0.02 (+0.18%)
Updated Jul 3, 2025
ROIV Price
$10.99
Fair Value Price
$1.34
Market Cap
$7.47B
52 Week Low
$8.73
52 Week High
$13.06
P/E
-45.79x
P/B
1.59x
P/S
251.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$29.05M
Earnings
-$171.98M
Gross Margin
96.9%
Operating Margin
-426.14%
Profit Margin
-592%
Debt to Equity
0.05
Operating Cash Flow
-$839M
Beta
0.84
Next Earnings
Aug 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ROIV Overview

Roivant Sciences Limited researches and develops medicines. It develops product candidates for the treatment of solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company's drug discovery capabilities include a computational physics-based platform for in silico drug design and machine learning-based models for protein degradation. Roivant was founded in 2014 and is headquartered in London, UK.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ROIV's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ROIV
Ranked
#326 of 468

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ROIV news, forecast changes, insider trades & much more!

ROIV News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ROIV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ROIV ($10.99) is overvalued by 719.5% relative to our estimate of its Fair Value price of $1.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ROIV ($10.99) is not significantly undervalued (719.5%) relative to our estimate of its Fair Value price of $1.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ROIV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ROIV due diligence checks available for Premium users.

Valuation

ROIV fair value

Fair Value of ROIV stock based on Discounted Cash Flow (DCF)

Price
$10.99
Fair Value
$1.34
Overvalued by
719.50%
ROIV ($10.99) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ROIV ($10.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ROIV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ROIV price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-45.79x
Industry
-154.26x
Market
30.96x

ROIV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.59x
Industry
4.54x
ROIV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ROIV's financial health

Profit margin

Revenue
$7.6M
Net Income
-$206.5M
Profit Margin
-2,727.5%
ROIV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ROIV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$5.4B
Liabilities
$249.7M
Debt to equity
0.05
ROIV's short-term assets ($5.00B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ROIV's short-term assets ($5.00B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ROIV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ROIV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$172.6M
Investing
$1.1B
Financing
-$177.2M
ROIV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ROIV vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ROIVD$7.47B+0.18%-45.79x1.59x
CORTC$7.66B+1.30%56.91x11.22x
VRNAC$7.79B+1.61%-45.77x34.39x
RVMDD$7.05B+1.83%-9.44x3.39x
IONSC$6.84B-1.35%-14.38x14.39x

Roivant Sciences Stock FAQ

What is Roivant Sciences's quote symbol?

(NASDAQ: ROIV) Roivant Sciences trades on the NASDAQ under the ticker symbol ROIV. Roivant Sciences stock quotes can also be displayed as NASDAQ: ROIV.

If you're new to stock investing, here's how to buy Roivant Sciences stock.

What is the 52 week high and low for Roivant Sciences (NASDAQ: ROIV)?

(NASDAQ: ROIV) Roivant Sciences's 52-week high was $13.06, and its 52-week low was $8.73. It is currently -15.82% from its 52-week high and 25.89% from its 52-week low.

How much is Roivant Sciences stock worth today?

(NASDAQ: ROIV) Roivant Sciences currently has 679,806,070 outstanding shares. With Roivant Sciences stock trading at $10.99 per share, the total value of Roivant Sciences stock (market capitalization) is $7.47B.

Roivant Sciences stock was originally listed at a price of $9.84 in Oct 7, 2020. If you had invested in Roivant Sciences stock at $9.84, your return over the last 4 years would have been 11.69%, for an annualized return of 2.8% (not including any dividends or dividend reinvestments).

How much is Roivant Sciences's stock price per share?

(NASDAQ: ROIV) Roivant Sciences stock price per share is $10.99 today (as of Jul 3, 2025).

What is Roivant Sciences's Market Cap?

(NASDAQ: ROIV) Roivant Sciences's market cap is $7.47B, as of Jul 7, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Roivant Sciences's market cap is calculated by multiplying ROIV's current stock price of $10.99 by ROIV's total outstanding shares of 679,806,070.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.